[非匹配病例与对照研究：高同型半胱氨酸血症与慢性缺血性心脏病]

[Study of unmatched cases and controls: hyperhomocysteinaemia and chronic ischaemic cardiopathy].

作者信息

Gallego-Luis R, Ruiz-García A, Gordillo-López F J, Díaz-Puente M V, Esteban J, Gil de Miguel A

机构信息

Unidad de Lípidos y Prevención Cardiovascular, Area 10 Atención Primaria IMSALUD, Madrid, Spain.

出版信息

Aten Primaria. 2006 Apr 15;37(6):325-31. doi: 10.1157/13086709.

DOI:10.1157/13086709

PMID:16733005

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7679868/

Abstract

OBJECTIVE

To evaluate the extent of the association between hyperhomocysteinaemia and chronic ischaemic heart disease.

DESIGN

Unmatched, case-control (1:3) study.

SETTING

Pintores Health Centre, Area 10, Primary Care, Madrid, Spain.

PARTICIPANTS

Patients of the health centre over 35 with chronic ischaemic heart disease or without it.

METHOD

Consecutive, non-randomized sample. Analysis of cases and controls with chi2 test and odds ratio (OR). The quantitative variables were analysed with the Student's t test.

RESULTS

The 76.32% (87/114) of cases had 2 or more cardiovascular risk factors versus 33.56% (99/265) in the control group (P<.0001). Average homocysteinaemia was 10.07 micromol/L (SD, 3.64) in the control group; and 12.74 (SD, 4.59) in the cases group. The difference between the averages (2.67 micromol/L; 95% CI, 1.82-3.52) was significant (P<.001). The difference (16.07%; 95% CI, 6.91-25.23) in hyperhomocysteinaemia (> or =15 micromol/L) between cases (28.95%, 33/114) and controls (12.88%, 38/295) was significant (P=.0001), with an association between hyperhomocysteinaemia and chronic ischaemic heart disease (OR=2.76; 95% CI, 1.62-4.68). This association increased (OR=3.26; 95% CI, 2.07-5.13) when hyperhomocysteinaemia was taken as > or =12 micromol/L, with a significant difference of 27% (95% CI, 16.59-37.41) (P<.0001) between cases (51.75%, 59/114) and controls (24.75%, 73/295).

CONCLUSIONS

The risk factor of hyperhomocysteinaemia > or =15 micromol/L was significantly associated (OR=2.76) with chronic ischaemic heart disease. This association was greater (OR=3.26) when hyperhomocysteinaemia was taken as > or =12 micromol/L.

摘要

目的

评估高同型半胱氨酸血症与慢性缺血性心脏病之间的关联程度。

设计

非匹配病例对照（1:3）研究。

地点

西班牙马德里第10区平托雷斯健康中心，初级保健机构。

参与者

该健康中心35岁以上患有或未患有慢性缺血性心脏病的患者。

方法

连续非随机抽样。采用卡方检验和比值比（OR）对病例组和对照组进行分析。定量变量采用学生t检验进行分析。

结果

76.32%（87/114）的病例有2种或更多心血管危险因素，而对照组为33.56%（99/265）（P<0.0001）。对照组平均同型半胱氨酸血症为10.07微摩尔/升（标准差，3.64）；病例组为12.74（标准差，4.59）。平均值之间的差异（2.67微摩尔/升；95%可信区间，1.82 - 3.52）具有显著性（P<0.001）。病例组（28.95%，33/114）和对照组（12.88%，38/295）之间高同型半胱氨酸血症（≥15微摩尔/升）的差异（16.07%；95%可信区间，6.91 - 25.23）具有显著性（P = 0.0001），高同型半胱氨酸血症与慢性缺血性心脏病之间存在关联（OR = 2.76；95%可信区间，1.62 - 4.68）。当高同型半胱氨酸血症≥12微摩尔/升时，这种关联增强（OR = 3.26；95%可信区间，2.07 - 5.13），病例组（51.75%，59/114）和对照组（24.75%，73/295）之间差异显著为27%（95%可信区间，16.59 - 37.41）（P<0.0001）。